{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-077061","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2023-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.104684+00:00","generated_at":"2026-06-13T14:07:59.328375+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Black Diamond Therapeutics raises ~$71.6M in public offering of 15M shares at $5.00/share","bullets":["Underwritten public offering of 15,000,000 shares at $5.00/share; net proceeds ~$71.6M.","Underwriters have 30-day option to buy up to 2,250,000 additional shares (full exercise net ~$82.4M).","Proceeds to advance clinical pipeline including BDTX-1535 for non-small cell lung cancer and for working capital.","Underwriting agreement with Piper Sandler & Co.; officers/directors subject to 60-day lock-up.","Offering expected to close July 5, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-077061","json":"https://secwatch.observer/filing/0001104659-23-077061.json","markdown":"https://secwatch.observer/filing/0001104659-23-077061.md","text":"https://secwatch.observer/filing/0001104659-23-077061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923077061/0001104659-23-077061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923077061/tm2320300d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:07:59.328375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9cae59ed51577936cf1f76e46ceea5541e24fe9","claim":"Black Diamond Therapeutics, Inc. entered into Underwriting Agreement with Piper Sandler & Co., as representative of the several underwriters valued at approximately $71.6 million (effective 2023-06-29).","evidence_excerpt":"On June 29, 2023, Black Diamond Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., as representative of the several underwriters named in Schedule 1 thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 15,000,000 shares (the “Shares”) of common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923077061/0001104659-23-077061-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Piper Sandler & Co., as representative of the several underwriters"},{"label":"Value","value":"approximately $71.6 million"},{"label":"Effective","value":"2023-06-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}